XML 190 R32.htm IDEA: XBRL DOCUMENT v3.20.4
Company Operations by Product, Customer and Geographic Area
 12 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Company Operations by Product, Customer and Geographic Area Company Operations by Product, Customer and Geographic Area 
We have determined that we operate in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on our proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the CEO. The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. 
The following table presents a summary of total revenues by these products for the twelve months ended December 31, 2020, 2019, and 2018: 

 Revenue by Product: 202020192018
Bloxiverz$2,201 $7,479 $20,850 
Vazculep10,429 33,152 42,916 
Akovaz9,545 18,642 33,759 
Other159 (58)3,898 
Product sales22,334 59,215 101,423 
License revenue— — 1,846 
Total revenues$22,334 $59,215 $103,269 
 
Concentration of credit risk with respect to accounts receivable is limited due to the high credit quality comprising a significant portion of the Company’s customers. Management periodically monitors the creditworthiness of our customers and believes that we have adequately provided for any exposure to potential credit loss.

The following table presents a summary of total revenues by significant customer for the twelve months ended December 31, 2020, 2019, and 2018: 
Revenue by Significant Customer:202020192018
McKesson Corporation$5,758 $14,900 $26,794 
Cardinal Health5,155 15,088 25,413 
AmerisourceBergen 3,155 12,059 18,620 
QuVa Pharma3,117 3,252 2,788 
Others5,149 13,916 27,808 
Product sales22,334 59,215 101,423 
License revenue— — 1,846 
Total revenues$22,334 $59,215 $103,269 
The following table summarizes revenues by geographic region for the twelve months ended December 31, 2020, 2019, and 2018:
Revenue by Geographic Region: 202020192018
   
U.S.$22,334 $59,215 $101,423 
Ireland— — 1,846 
Total revenues$22,334 $59,215 $103,269 
Currently, we are working with contract manufacturing organizations for the manufacture of FT218. Additionally, we purchase raw materials used in FT218 from a limited number of suppliers, including a single supplier for certain key ingredients.
Non-monetary long-lived assets primarily consist of property and equipment, goodwill, intangible assets and operating right-of use-assets. The following table summarizes non-monetary long-lived assets by geographic region as of December 31, 2020, 2019, and 2018:
Long-lived Assets by Geographic Region: 202020192018
   
U.S.$20,424 $22,254 $27,761 
France11 196 1,365 
Ireland6,047 7,244 6,028 
Total$26,482 $29,694 $35,154